7.66
price up icon0.13%   0.010
after-market Handel nachbörslich: 7.66
loading
Schlusskurs vom Vortag:
$7.65
Offen:
$7.83
24-Stunden-Volumen:
402.27K
Relative Volume:
2.08
Marktkapitalisierung:
$470.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-159.39M
KGV:
-2.1638
EPS:
-3.5401
Netto-Cashflow:
$-105.22M
1W Leistung:
+15.19%
1M Leistung:
+27.24%
6M Leistung:
+4.64%
1J Leistung:
-43.51%
1-Tages-Spanne:
Value
$7.41
$7.83
1-Wochen-Bereich:
Value
$6.52
$8.06
52-Wochen-Spanne:
Value
$4.77
$14.16

Abivax Adr Stock (ABVX) Company Profile

Name
Firmenname
Abivax Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
69
Name
Twitter
Name
Nächster Verdiensttermin
2025-06-02
Name
Neueste SEC-Einreichungen
Name
ABVX's Discussions on Twitter

Vergleichen Sie ABVX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABVX
Abivax Adr
7.66 470.70M 0 -159.39M -105.22M -3.5401
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Abivax Adr Stock (ABVX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-20 Eingeleitet Morgan Stanley Equal-Weight
2024-12-04 Eingeleitet JMP Securities Mkt Outperform
2024-07-29 Eingeleitet Laidlaw Buy
2024-05-20 Eingeleitet BTIG Research Buy
2024-04-29 Eingeleitet Guggenheim Buy
2024-04-29 Eingeleitet Piper Sandler Overweight
2023-11-14 Eingeleitet Leerink Partners Outperform
2023-11-14 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Abivax Adr Aktie (ABVX) Neueste Nachrichten

pulisher
Jun 12, 2025

Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks

Jun 11, 2025
pulisher
Jun 11, 2025

Abivax Announces Results of its June 6, 2025 Annual General Meeting - GlobeNewswire Inc.

Jun 11, 2025
pulisher
Jun 09, 2025

European ADRs Edge Up As Wisekey And ASML Lead Gains - Finimize

Jun 09, 2025
pulisher
Jun 04, 2025

Promising Outlook for Abivax’s Obefazimod in Ulcerative Colitis with Upcoming Phase 3 Results as Key Catalyst - TipRanks

Jun 04, 2025
pulisher
Jun 02, 2025

Abivax SA Reports Increased Losses Amid R&D Expansion - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Abivax Reports First Quarter 2025 Financial Results with Increased R&D Costs - TipRanks

Jun 02, 2025
pulisher
May 14, 2025

Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity - TipRanks

May 14, 2025
pulisher
Apr 29, 2025

Abivax Completes Enrollment for Phase 3 Ulcerative Colitis Trials - TipRanks

Apr 29, 2025
pulisher
Apr 22, 2025

Abivax Announces AGM Details and Board Appointment Amid 2025 Milestones - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Abivax ADR (NASDAQ: ABVX) – Does It Provide Stability And Growth? - Stocksregister

Apr 18, 2025
pulisher
Apr 08, 2025

Abivax Reports 2024 Financial Results, Eyes Clinical Milestones - TipRanks

Apr 08, 2025
pulisher
Mar 27, 2025

Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 25, 2025

Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Abivax SA’s Obefazimod: A Promising Blockbuster in Ulcerative Colitis Treatment - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Positive Outlook for Abivax: Buy Rating Supported by Promising Phase 3 Trials and Strong Financial Position - TipRanks

Mar 24, 2025
pulisher
Mar 18, 2025

Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025 - TipRanks

Mar 18, 2025
pulisher
Mar 17, 2025

Buy Rating for Abivax: Promising Potential of Obefazimod in Ulcerative Colitis Treatment - TipRanks

Mar 17, 2025
pulisher
Mar 01, 2025

Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High? - MSN

Mar 01, 2025
pulisher
Feb 24, 2025

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year? - Nasdaq

Feb 24, 2025
pulisher
Feb 11, 2025

Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet - Yahoo Finance

Feb 11, 2025
pulisher
Feb 10, 2025

Potential Price Increase for Abivax ADR (ABVX) After Recent Insider Activity - Knox Daily

Feb 10, 2025
pulisher
Feb 10, 2025

Sibanye Stillwater Limited ADR (SBSW) rating downgrades by HSBC Securities - Knox Daily

Feb 10, 2025
pulisher
Feb 07, 2025

Quantum Corp (QMCO) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of Abivax ADR (ABVX) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Capricor Therapeutics Inc (CAPR) Shares Plummet Below 1-Year High - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Paylocity Holding Corp’s (PCTY) Stock: A Long-Term Performance Analysis - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Perrigo Company plc (PRGO) Stock: A Closer Look at the Moving Averages - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Analyzing the Price-to-Earnings Ratio of ICL Group Ltd (ICL) - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Tectonic Therapeutic Inc (TECX) Stock: A Review of the Recent Movement - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Healthcare Triangle Inc (HCTI) Stock: A Closer Look at the Market Potential - The News Heater

Feb 07, 2025
pulisher
Jan 30, 2025

Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks - MSN

Jan 30, 2025
pulisher
Oct 26, 2023

Citi Appointed as Depositary Bank for Abivax SA’s ADR Program - Business Wire

Oct 26, 2023

Finanzdaten der Abivax Adr-Aktie (ABVX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):